These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 26933949

  • 1. ESA Hyporesponsiveness Is Associated with Adverse Events in Maintenance Hemodialysis (MHD) Patients, But Not with Iron Storage.
    Kuragano T, Kitamura K, Matsumura O, Matsuda A, Hara T, Kiyomoto H, Murata T, Fujimoto S, Hase H, Joki N, Fukatsu A, Inoue T, Itakura Y, Nakanishi T.
    PLoS One; 2016; 11(3):e0147328. PubMed ID: 26933949
    [Abstract] [Full Text] [Related]

  • 2. Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study.
    Ogawa T, Shimizu H, Kyono A, Sato M, Yamashita T, Otsuka K, Nitta K.
    Int Urol Nephrol; 2014 Jan; 46(1):151-9. PubMed ID: 23807369
    [Abstract] [Full Text] [Related]

  • 3. High-volume online haemodiafiltration improves erythropoiesis-stimulating agent (ESA) resistance in comparison with low-flux bicarbonate dialysis: results of the REDERT study.
    Panichi V, Scatena A, Rosati A, Giusti R, Ferro G, Malagnino E, Capitanini A, Piluso A, Conti P, Bernabini G, Migliori M, Caiani D, Tetta C, Casani A, Betti G, Pizzarelli F.
    Nephrol Dial Transplant; 2015 Apr; 30(4):682-9. PubMed ID: 25385719
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients.
    Kalantar-Zadeh K, Lee GH, Miller JE, Streja E, Jing J, Robertson JA, Kovesdy CP.
    Am J Kidney Dis; 2009 May; 53(5):823-34. PubMed ID: 19339087
    [Abstract] [Full Text] [Related]

  • 8. Achievement of renal anemia KDIGO targets by two different clinical strategies - a European hemodialysis multicenter analysis.
    Drozdz M, Weigert A, Silva F, Frazão J, Alsuwaida A, Krishnan M, Kleophas W, Brzosko S, Johansson FK, Jacobson SH.
    BMC Nephrol; 2019 Jan 07; 20(1):5. PubMed ID: 30616548
    [Abstract] [Full Text] [Related]

  • 9. The safety of achieved iron stores and their effect on IV iron and ESA use: post-hoc results from a randomized trial of ferric citrate as a phosphate binder in dialysis
.
    Umanath K, Greco B, Jalal DI, McFadden M, Sika M, Koury MJ, Niecestro R, Hunsicker LG, Greene T, Lewis JB, Dwyer JP.
    Clin Nephrol; 2017 Mar 07; 87 (2017)(3):124-133. PubMed ID: 28128726
    [Abstract] [Full Text] [Related]

  • 10. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T.
    Ther Apher Dial; 2010 Jun 07; 14(3):240-75. PubMed ID: 20609178
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients.
    Rivara MB, Ikizler TA, Ellis CD, Mehrotra R, Himmelfarb J.
    BMC Nephrol; 2015 Jun 05; 16():79. PubMed ID: 26045064
    [Abstract] [Full Text] [Related]

  • 13. Low levels of serum ferritin and moderate transferrin saturation lead to adequate hemoglobin levels in hemodialysis patients, retrospective observational study.
    Ogawa C, Tsuchiya K, Tomosugi N, Kanda F, Maeda K, Maeda T.
    PLoS One; 2017 Jun 05; 12(6):e0179608. PubMed ID: 28662118
    [Abstract] [Full Text] [Related]

  • 14. Thresholds of iron markers for iron deficiency erythropoiesis-finding of the Japanese nationwide dialysis registry.
    Hamano T, Fujii N, Hayashi T, Yamamoto H, Iseki K, Tsubakihara Y.
    Kidney Int Suppl (2011); 2015 Jun 05; 5(1):23-32. PubMed ID: 26097782
    [Abstract] [Full Text] [Related]

  • 15. Oral zinc supplementation reduces the erythropoietin responsiveness index in patients on hemodialysis.
    Kobayashi H, Abe M, Okada K, Tei R, Maruyama N, Kikuchi F, Higuchi T, Soma M.
    Nutrients; 2015 May 15; 7(5):3783-95. PubMed ID: 25988769
    [Abstract] [Full Text] [Related]

  • 16. TSAT is a better predictor than ferritin of hemoglobin response to Epoetin alfa in US dialysis patients.
    Gaweda AE, Bhat P, Maglinte GA, Chang CL, Hill J, Park GS, Ashfaq A, Gitlin M.
    Hemodial Int; 2014 Jan 15; 18(1):38-46. PubMed ID: 23968235
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of Effect of Ascorbic Acid on Ferritin and Erythropoietin Resistance in Patients of Chronic Kidney Disease.
    Nand N, Deshmukh AR, Mittal R.
    J Assoc Physicians India; 2017 Jul 15; 65(7):32-36. PubMed ID: 28792166
    [Abstract] [Full Text] [Related]

  • 18. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in hemodialysis patients.
    Petrulienė K, Žiginskienė E, Kuzminskis V, Nedzelskienė I, Bumblytė IA.
    Medicina (Kaunas); 2017 Jul 15; 53(2):90-100. PubMed ID: 28416170
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.